Navigation Links
PLUS Diagnostics First National Laboratory to Offer Highly Specialized Gastrointestinal Tests
Date:6/1/2009

Company Expands Diagnostic Services with K9 Clone DOG-1 Immunohistochemical and H. pylori Monoclonal Antibody Tests

LAKEWOOD, N.J., June 1 /PRNewswire/ -- PLUS Diagnostics, a leading U.S. anatomic pathology company offering a full range of multi-specialty services, announced today that it is the first national laboratory to offer a highly specialized test that definitively diagnoses the rare gastrointestinal stromal tumor ("GIST"). Known as the K9 clone DOG-1 immunohistochemical assay, the new test is expected to identify up to 15 percent more people who suffer from the tumor than current tests.

PLUS Diagnostics also announced that it is the first U.S. laboratory to beta test an H. pylori monoclonal antibody test that detects H. pylori infection. Afflicting as many as 30 percent of Americans, H. pylori can be difficult to distinguish from other bacteria in routine staining assays. The infection, which is commonly caused by ingesting contaminated water or food, can cause peptic ulcer disease and gastric malignancy when left untreated. PLUS Diagnostics' new test is expected to reduce the number of false positive H. pylori cases.

"These tests are at the forefront of science and innovation, and support our goal of providing our customers with leading diagnostic services that enable them to offer their patients the highest quality of care," said Doug Berg, chief executive officer, PLUS Diagnostics. "We will continue to identify and invest in the newest tests and technologies that are uniquely tailored to supporting doctors and specialists with diagnosing a range of cancers and disorders."

Dr. Ali Riba, associate medical director for PLUS Diagnostics, added: "It is exciting to be part of a laboratory that is significantly investing in gastrointestinal services. We have the potential to help doctors save lives by definitively diagnosing the rare GIST tumor when traditional tests are not able to do so. Similarly, our beta test for H. pylori is expected to improve the accuracy of today's immunohistochemical tests, so doctors can immediately determine whether their patients require treatment."

PLUS Diagnostics has expanded its services since the company partnered with Water Street Healthcare Partners, a leading private equity firm focused exclusively on health care. It recently opened a West Coast laboratory and announced plans to expand into diagnostics services for hematology/oncology, in addition to the gastroenterology and urology specialties it serves today.

About PLUS Diagnostics

PLUS Diagnostics is a leading national anatomic pathology company that provides a full range of multi-specialty services, including extensive diagnostic procedures and specialist consultations. Accredited by the College of American Pathologists, PLUS Diagnostics has long been recognized for exceptional service and quality. The company currently focuses on a broad base of specialty pathology services, including urology and gastroenterology with plans to expand into hematopathology this year. For more information, visit, www.plusdx.com.


'/>"/>
SOURCE PLUS Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Strategic Diagnostics Appoints Kevin J. Bratton as Chief Financial Officer
2. Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
3. Quest Diagnostics to Speak at the Deutsche Bank 34th Annual Healthcare Conference
4. Quest Diagnostics to Connect to Microsoft HealthVault and Empower Patients and Physicians to Share Diagnostic Laboratory Test Results Online
5. Quest Diagnostics Declares Quarterly Cash Dividend
6. Beckman Coulter Pending Acquisition of Olympus Diagnostics Systems Passes Milestone with U.S. Regulatory Approval
7. Quest Diagnostics Announces Annual Shareholders Meeting Webcast
8. Quest Diagnostics to Speak at the Bank of America and Merrill Lynch 2009 Healthcare Conference
9. Cocaine Use Among U.S. Workers Declines Sharply in 2008, According to Quest Diagnostics Drug Testing Index(TM)
10. Personalized Medicine Makes Significant Headway Following the Rapid Evolution of U.S. Molecular Diagnostics Market, Finds Frost & Sullivan
11. Instrumentation Laboratory Wins Patent Infringement and Unfair Competition Trial Against Diagnostica Stago Relating to Reagents for Hemostasis Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: